These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 27272266)

  • 41. A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.
    Kiang TK; Wilby KJ; Ensom MH
    Clin Pharmacokinet; 2015 Sep; 54(9):915-31. PubMed ID: 25940827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current guidelines for the treatment of severe pneumonia and sepsis.
    Bodmann KF
    Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.
    Kimko H; Murthy B; Xu X; Nandy P; Strauss R; Noel GJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1228-30. PubMed ID: 19075059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a 
    Welte T; Scheeren TW; Overcash JS; Saulay M; Engelhardt M; Hamed K
    Future Microbiol; 2021 May; 16():543-555. PubMed ID: 33960817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study.
    Carrié C; Chadefaux G; Sauvage N; de Courson H; Petit L; Nouette-Gaulain K; Pereira B; Biais M
    Crit Care; 2019 Nov; 23(1):379. PubMed ID: 31775840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
    Udy AA; Roberts JA; De Waele JJ; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2012 Jun; 39(6):455-7. PubMed ID: 22483562
    [No Abstract]   [Full Text] [Related]  

  • 48. CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy.
    Gentile I; Buonomo AR; Corcione S; Paradiso L; Giacobbe DR; Bavaro DF; Tiseo G; Sordella F; Bartoletti M; Palmiero G; Vozza A; Vena A; Canta F; Moriello NS; Congera P; Karruli A; Tascini C; Viale P; Bono VD; Falcone M; Carbonara S; Mikulska MK; Bassetti M; Durante-Mangoni E; De Rosa FG; Maraolo AE
    Int J Antimicrob Agents; 2023 Jul; 62(1):106817. PubMed ID: 37061102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria.
    Roos JF; Lipman J; Kirkpatrick CMJ
    Intensive Care Med; 2007 May; 33(5):781-788. PubMed ID: 17342515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A
    Huang H; Gao L; Engelhardt M; Saulay M; Hamed K
    Future Microbiol; 2021 Jul; 16():783-796. PubMed ID: 34155899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
    Boselli E; Breilh D; Rimmelé T; Djabarouti S; Saux MC; Chassard D; Allaouchiche B
    Crit Care Med; 2005 Jan; 33(1):104-9. PubMed ID: 15644655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
    Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftobiprole medocaril: a new generation beta-lactam.
    Del Pozo JL; Patel R
    Drugs Today (Barc); 2008 Nov; 44(11):801-25. PubMed ID: 19180259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
    Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ
    Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of ceftobiprole.
    Grau S
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):34-36. PubMed ID: 31364340
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients.
    Zasowski E; Bland CM; Tam VH; Lodise TP
    J Antimicrob Chemother; 2015 Mar; 70(3):877-81. PubMed ID: 25381169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
    Soto E; Shoji S; Muto C; Tomono Y; Marshall S
    Br J Clin Pharmacol; 2014 Mar; 77(3):509-21. PubMed ID: 24102758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.
    Mendes RE; Deshpande LM; Costello AJ; Farrell DJ; Jones RN; Flamm RK
    Microb Drug Resist; 2016 Jan; 22(1):53-8. PubMed ID: 26230870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.